Using Optical Coherence Tomography and Noninvasive Retinal Amyloid Imaging to Capture Retinal Changes Associated With Dementia

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Observational
SUMMARY

The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to: 1. Detect retinal blood vessel and blood flow changes in participants with dementia. 2. Detect amyloid protein deposits in the retinas of participants with dementia.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 55
Healthy Volunteers: t
View:

• Physician-confirmed diagnosis of probable Alzheimer's disease

• Mild dementia, as defined by score of 20 or greater on the Mini-Mental State Exam, or score of 15 or greater on the Montreal Cognitive Assessment, or Clinical Dementia Rating Scale score of 1.

• Age older than 55 years.

• Able to comply with study procedures

• Corrected visual acuity at least 20/400 in either eye.

• Has a legally authorized representative who can sign study consent form and accompany the participant to the OCT study visit.

• Age older than 55 years

• Able to comply with study procedures

• Able to maintain stable fixation for OCT imaging

• Corrected visual acuity of at least 20/40 in either eye

• Dementia-free, as defined by score of 24 or greater on the Mini-Mental Status Exam, or a score of 18 or greater on the Montreal Cognitive Assessment, or Clinical Dementia Rating of \<1.0.

Locations
United States
Oregon
Oregon Health & Science University
RECRUITING
Portland
Contact Information
Primary
Denzil Romfh, OD
romfhd@ohsu.edu
503-494-4351
Backup
Humberto Martinez, COT
martinhu@ohsu.edu
503-494-7712
Time Frame
Start Date: 2018-09-14
Estimated Completion Date: 2027-12
Participants
Target number of participants: 20
Treatments
Early Dementia
This group will consist of adults with suspected dementia/Alzheimer's Disease. OCTA and NRAI data will be gathered in one study visit.
Dementia-Free Controls
This group will consist of adults without suspected dementia/Alzheimer's Disease. OCTA and NRAI data will be gathered in one study visit.
Related Therapeutic Areas
Sponsors
Leads: Oregon Health and Science University

This content was sourced from clinicaltrials.gov